Actavis sells Foshan Pharma stake

Share this article:

Actavis's planned China departure is gaining speed. The company announced Friday that it is selling its interest in Foshan Pharmaceuticals to Zhejiang Chiral Medicine Chemicals Co., Ltd.

The company said in a statement that its plan is to “further commercial operations in China in collaboration with its preferred business partners,” but the firm has recently been talking about how the country's business climate is not friendly enough.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.